ELAHERE® (mirvetuximab soravtansine-gynx) for Injection, a …
WEBJan 19, 2024 · ELAHERE is a prescription medicine used to treat adults with folate receptor-alpha (FRɑ) positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not responded to or are no longer responding to treatment with platinum-based chemotherapy and
WEB• The recommended dose of ELAHERE is 6 mg/kg AIBW administered once every 3 weeks (21-day cycle) • ELAHERE is an IV infusion and is administered until disease progression or unacceptable toxicity • Dosing based on AIBW reduces exposure variability for patients who are either under- or overweight
Elahere: Uses, Dosage, Side Effects, Warnings - Drugs.com
WEBMar 28, 2024 · Elahere (mirvetuximab soravtansine-gynx) is an injectable antibody-drug conjugate that may be used to treat adults with folate receptor-alpha (FRα) -positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have alr.
FDA approves mirvetuximab soravtansine-gynx (Elahere, …
WEBOn March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα positive,...
Eye Care | ELAHERE® (mirvetuximab soravtansine-gynx) | HCP …
WEBELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
WEBELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial...
Considering Elahere For Your Ovarian Cancer? Here's What
WEBOct 25, 2023 · A new breakthrough drug, Elahere (generic name: mirvetuximab soravtansine-gynx) offers hope to certain patients with ovarian cancers that have become resistant to conventional treatments and whose tumors express a high level of a protein on their surface, namely folate receptor-α (FRα).
FDA grants accelerated approval to mirvetuximab soravtansine …
WEBOn November 14, 2022, the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.) for adult patients with folate receptor alpha...
Elahere Intravenous: Uses, Side Effects, Interactions, Pictures ... - WebMD
WEBElahere 5 Mg/Ml Intravenous Solution Antineoplastic Monoclonal Antibodies - Uses, Side Effects, and More. Generic Name (S): mirvetuximab soravtansine-gynx. Uses. This medication is used to treat...
Managing An Ovarian Cancer Recurrence: How The New Drug Elahere …
WEBAug 1, 2023 · Elahere (generic name mirvetuximab soravtansine) has shown a 33% improvement in survival for platinum resistant ovarian cancer, according to the Chief Medical Officer of ImmunoGen. To know if you are eligible, you must take a special test called a immunohistochemistry (IHC).
Skip to content